Gene fusions involving NTRK genes that lead to transcription of chimeric Trk proteins with constitutively activate or overexpressed kinase function conferring oncogenic potential have become increasingly important targets for cancer therapy (Cocco et al., 2018; Lange and Lo, 2018). This evidence concerns the gene NTRK1 and cancer.